TechnipFMC (FTI) 8-KDeparture of Directors or Certain Officers

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

July 25, 2023

Date of Report (Date of earliest event reported)

TechnipFMC plc

(Exact name of registrant as specified in its charter)

+1 281-591-4000

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

The Board of Directors of TechnipFMC plc (the “Company”) has appointed Cristina Aalders, the Company’s Chief Compliance Officer, as Executive Vice President, Chief Legal Officer and Secretary, effective July 31, 2023. Ms. Aalders succeeds Victoria Lazar, who will no longer serve as Executive Vice President, Chief Legal Officer and Secretary of the Company effective July 31, 2023. Ms. Lazar will continue as an employee of the Company through August 31, 2023, to ensure an orderly transition of her duties.

In connection with Ms. Lazar’s departure, the Company entered into a Separation, Release and Waiver of Claims and Restrictive Covenant Agreement (the “Agreement”), dated July 31, 2023, pursuant to which Ms. Lazar will be entitled to the following benefits: (a) payment equal to two times the sum of her base salary and annual target bonus, payable over 48 bi-weekly pay periods, (b) a pro rata bonus for 2023 based on target performance, payable within 30 days of her separation, (c) the full cost of medical, dental and vision benefits for up to 18 months or, if earlier, the date she is eligible for coverage under another employer’s group medical, dental and vision plans, (d) tax preparation assistance for her years of employment, and (e) up to twelve months of outplacement services, in exchange for a release of claims, her continued compliance with 24-month post-termination non-competition and non-solicitation covenants, her ongoing cooperation with the Company, a mutual non-disparagement covenant and covenants regarding confidential information.

The foregoing summary of the Agreement does not purport to be complete and is qualified in its entirety by the complete text of the Agreement, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.

(d) Exhibits

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.